scholarly journals BERT based Adverse Drug Effect Tweet Classification

Author(s):  
Tanay Kayastha ◽  
Pranjal Gupta ◽  
Pushpak Bhattacharyya
2019 ◽  
Vol 176 ◽  
pp. 33-41
Author(s):  
Ed-drissiya El-allaly ◽  
Mourad Sarrouti ◽  
Noureddine En-Nahnahi ◽  
Said Ouatik El Alaoui

1992 ◽  
Vol 20 (3-2) ◽  
pp. 501-505 ◽  
Author(s):  
Dai T. Davies

This short paper will briefly discuss the merits of determining plasma enzyme activities in pre-clinical safety evaluation. Emphasis is placed on the value of selecting the appropriate enzymes and collecting blood samples at the appropriate times during the study, so as to gain the maximum amount of diagnostic information. Examples of actual results will be cited to illustrate some of the points. These examples are drawn from the 2 commonly used toxicology species—the laboratory white rat and the beagle—and serve to demonstrate the importance of enzymology in monitoring the progress or resolution of an adverse drug effect.


2003 ◽  
Vol 48 (1) ◽  
pp. 67-68 ◽  
Author(s):  
Cara J. Krulewitch

2020 ◽  
Vol 25 (1) ◽  
pp. 64-67 ◽  
Author(s):  
Amy P. Holmes ◽  
Charles E. Hartis ◽  
Laurie J. Rollins

Limited data exist regarding the use of fluoroquinolones in the neonatal population. Levofloxacin has some utility in this population because it is one of a very limited number of antibiotics with activity against Stenotrophomonas maltophilia. We describe the successful treatment of S maltophilia tracheitis in a premature neonate using levofloxacin 10 mg/kg every 24 hours and the subsequent unexpected sharp rise in the direct bilirubin. This case illustrates a previously unrecognized adverse drug effect associated with levofloxacin use in neonates.


2021 ◽  
Author(s):  
Nicholas P. Giangreco ◽  
Nicholas P. Tatonetti

AbstractBackgroundIdentifying adverse drugs effects (ADEs) in children is essential for preventing disability and death from marketed drugs. At the same time, however, detection is challenging due to dynamic biological processes during growth and maturation, called ontogeny, that alter pharmacokinetics and pharmacodynamics. As a result, current data mining methodologies have been limited to event surveillance and have not focused on investigating adverse event mechanisms. There is an opportunity to design data mining methodologies to identify and evaluate drug event patterns within observational databases for ontogenic-mediated adverse event mechanisms. The first step of which is to establish statistical models that can identify temporal trends of adverse effects across childhood.ResultsUsing simulation, we evaluated a population stratification method (the proportional reporting ratio or PRR) and a population modeling method (the generalized additive model or GAM) to identify and quantify ADE risk at varying reporting rates and dynamics. We found that GAMs showed improved performance over the PRR in detecting dynamic drug event reporting across child developmental stages. Moreover, GAMs exhibited normally distributed and robust ADE risk estimation at all development stages by sharing information across child development stages.ConclusionsOur study underscores the opportunity for using population modeling techniques, which leverages drug event reporting across development stages, to identify adverse drug effect risk resulting from ontogenic mechanisms.


Sign in / Sign up

Export Citation Format

Share Document